An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes

Launched by SECOND AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY · Apr 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Henggliflozin to see how safe and effective it is for Chinese patients with type 2 diabetes. The main goal is to find out if this medication can help manage blood sugar levels and improve other health indicators like blood pressure and weight. The trial will also look at any potential side effects, such as infections or other health issues that might arise during treatment.

To participate in this study, individuals need to be between 18 and 80 years old and have been diagnosed with type 2 diabetes. They should either currently be receiving treatment for diabetes or be eligible to add Henggliflozin to their treatment plan. It's important to note that people who have had frequent urinary tract infections or are currently in other diabetes trials will not be able to join. If someone decides to participate, they will need to sign a consent form, and those who may have difficulty understanding the form can have a witness help them. Overall, this study aims to gather real-world information about Henggliflozin and how it impacts the health of people with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years old≤ age ≤ 80 years old;
• • 2. Diagnosed with type 2 diabetes mellitus according to WHO diagnostic criteria, currently receiving or eligible for add-on therapy with Henagliflozin;
• • 3. Voluntarily participate in this study and sign the informed consent form. If the subject does not have the ability to read the informed consent form (e.g., illiterate subjects), a witness is required to witness the informed process and sign the informed consent form.
• Exclusion Criteria:
• • 1. Participation in or current enrollment in clinical trials investigating other glucose-lowering medications within 1 month prior to the initiation of this study.
• • 2. Current or history of recurrent urinary tract infections (UTIs) and/or genital infections.
• • 3. Patients judged by the investigator to be unsuitable to participate in this clinical trial, with considerations such as current blood volume status, estimated glomerular filtration rate (eGFR), and other clinical parameters.